Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL [5]

Leukemia

Volumn 17, Issue 10, 2003, Pages 2056-2057

  Dalle, J H ^a   Leblond, P ^a   Decouvelaere, A ^a   Yakoub Agha, I ^a   Preudhomme, C ^a   Nelken, B ^a   Mazingue, F ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THALIDOMIDE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE ATROPHY; CANCER RESISTANCE; CASE REPORT; CHIMERA; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HISTIOCYTIC SARCOMA; HLA MATCHING; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKEMIA REMISSION; MALE; NEUROLOGIC DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SARCOMA; T LYMPHOCYTE; BONE MARROW TRANSPLANTATION; HISTIOCYTIC LYMPHOMA; PATHOLOGY; SECOND CANCER; T CELL LEUKEMIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; HUMANS; LEUKEMIA, T-CELL, ACUTE; LYMPHOMA, LARGE-CELL; MALE; NEOPLASMS, SECOND PRIMARY; SARCOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0142151224     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403075     Document Type: Letter

References (8)

1. Elghetany MT. True histiocytic lymphoma: is it an entity? Leukemia 1997; 11: 762-764.
2. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Croup based on 61 cases. Histopathology 2002; 41: 1-29.
3. Ralfkiaer E, Delsol G, O'Connor NT, Brandtzaeg P, Brousset P, Vejlsgaard GL et al. Malignant lymphomas of true histiocytic origin. A clinical, histological, immunophenotypic and genotypic study. J Pathol 1990; 160: 9-17.
4. Soslow RA, Davis RE, Warnke RA, Cleary ML, Kamel OW. True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Blood 1996; 87: 5207-5212.
5. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274-1276.
6. Bessmertny O, Pham T. Thalidomide use in pediatric patients. Ann Pharmacother 2002; 36: 521-525.
7. Baidas S, Tfayli A, Bhargava P. Thalidomide: an old drug with new clinical applications. Cancer Invest 2002; 20: 835-848.
8. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950-1961.